✦ LIBER ✦

THE EFFICACY AND SAFETY OF TICAGRELOR AS COMPARED TO CLOPIDOGREL, WITH AND WITHOUT A GLYCOPROTEIN IIB/IIIA INHIBITOR IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PERCUTANEOUS INTERVENTION: A PLATO (STUDY OF PLATELET INHIBITION AND PATIENT OUTCOMES) ANALYSIS

✍ Scribed by Bansilal, Sameer; Wiviott, Stephen; Becker, Richard; Harrington, Robert; Himmelmann, Anders; Neely, Benjamin; Husted, Steen; Storey, Robert; Steg, Philippe; Katus, Hugo; James, Stefan; Wallentin, Lars; Cannon, Christopher

Book ID: 122979544
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 249 KB
Volume: 61
Category: Article
ISSN: 1558-3597
DOI: 10.1016/S0735-1097(13)61858-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of argatroban with o

Efficacy and safety of argatroban with or without glycoprotein IIb/IIIa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome

✍ Ignacio Cruz-Gonzalez; Maria Sanchez-Ledesma; Suzanne J. Baron; Josephine L. Hea 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 138 KB

Ticagrelor Versus Clopidogrel in Patient

Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis

✍ Steg, P. G.; James, S.; Harrington, R. A.; Ardissino, D.; Becker, R. C.; Cannon, 📂 Article 📅 2010 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 985 KB

Safety and Efficacy of Bivalirudin With

Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial

✍ Harvey D. White; E. Magnus Ohman; A. Michael Lincoff; Michel E. Bertrand; Antoni 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 571 KB

The Efficacy and Safety of Prasugrel Wit

The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention: A TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis In Myocardial Infarction 38) Analysis

✍ Michelle O'Donoghue; Elliott M. Antman; Eugene Braunwald; Sabina A. Murphy; P. G 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 480 KB

Effectiveness and safety of glycoprotein

Effectiveness and safety of glycoprotein IIb/IIIa inhibitors in patients with myocardial infarction undergoing primary percutaneous coronary intervention: A meta-analysis of observational studies

✍ Remi Kouz; Simon Kouz; Erick Schampaert; Stephane Rinfret; Jean-Claude Tardif; M 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 759 KB

DO WE STILL NEED A GLYCOPROTEIN IIB/IIIA

DO WE STILL NEED A GLYCOPROTEIN IIB/IIIA INHIBITOR FOR ACUTE ST-SEGMENT-ELEVATION MYOCARDIAL INFARCTION IN PATIENTS UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION AND PRETREATED WITH A LOADING DOSE OF CLOPIDOGREL?

✍ Lili Dong; Yongshi Wang; Xianhong Shu 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 239 KB